A
ADMA Biologics
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics
About ADMA Biologics
ADMA Biologics, accessible at admabiologics.com, is a biopharmaceutical company dedicated to improving the lives of immunocompromised patients and those at risk for certain infections. The company specializes in developing and manufacturing plasma-derived therapeutics, which are medications made from human plasma to treat and prevent diseases. ADMA operates in the healthcare and biotechnology market, focusing on providing innovative solutions for immune-compromised individuals.
ADMA Biologics serves a specific clientele, primarily authorized U.S. healthcare providers who are trained to prescribe or supply medicinal products. These healthcare providers rely on ADMA's products to treat patients with immune deficiencies and other related conditions. The company's business model is multifaceted, encompassing both the collection of human plasma through its subsidiary, ADMA BioCenters, and the production of plasma-derived therapies.
ADMA Biologics generates revenue through several streams. Firstly, it collects human plasma, which is then processed into specialized medications. Secondly, the company offers contract manufacturing services, providing a full suite of Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) opportunities. This means that ADMA not only produces its own products but also manufactures products for other companies, leveraging its expertise and facilities.
The company is led by Mr. Grossman, who has been with ADMA Biologics since its early days and has played a crucial role in its development and growth. Under his leadership, ADMA has secured several patents that form the basis of its manufacturing methods and product compositions.
In summary, ADMA Biologics is a pioneering biopharmaceutical company focused on plasma-derived therapies, serving healthcare providers and patients with immune deficiencies. It operates through plasma collection, product manufacturing, and contract services, ensuring a diversified revenue stream.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2013
- Outcome tier
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
News
Open roles
ADMA Biologics in the Ramsey ecosystem
The ADMA Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
Biomark Capital
Hercules Capital
Oxford Finance
Marathon Asset Management
Perceptive Advisors
Hayfin Capital Management
Ares Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
5 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about ADMA Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ADMA Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


